Our Team.
M. Levent Selamoglu
Levent is a pharmaceutical industry veteran with c. 30 years of pharma industry experience across Europe, Middle East & North Africa. Levent was formerly the CEO and Chairman of Mustafa Nevzat Pharma (“MN Pharma”), a leading FDA-approved and fully integrated (API to finished form) injectable generics pharma company which was sold to Amgen, Inc. for $700m in 2012. Prior to MN Pharma Levent held various leadership roles at GlaxoSmithKline for c. 12 years. Levent is currently a Board Member of Phamactive (generic pharma), Imuneks Pharma (OTC) and Polus Global (biologics). Levent is also a Board Member of the Turkish Pharma Manufacturers’ Association, Bosphorus University and Executive Committee Member for Pharmaceuticals at the Turkish Scientific & Technical Research Association (TUBITAK).
Kiren L. Naidoo
Kiren is a former pharma industry-focused investment banker, most recently a senior Vice President at BofA Merrill Lynch in London. Kiren’s expertise include M&A and financing across generic pharma, specialty pharma and consumer health. Some of Kiren’s most notable transactions include: Sale of MN Pharma to Amgen ($700m), Sale of Bedford Laboratories (Boehringer Ingelheim) to Hikma ($300m), Swap of Boehringer Ingelheim’s Consumer Healthcare Business with Sanofi’s Animal Health Business (Merial) (€22bn) and the Financing of Teva’s acquisition of Allergan Generics (Actavis) ($40.5bn).